OptimizeRx Corp.

OPRX

NASDAQHealthcareMedical - Healthcare Information Services

Open in GoAI

Previous close

$7.71

−$0.25 · -3.14%

Aug 21, 4:00 PM ET

Pre-market

$7.60

−$0.11 · -1.43%

Aug 24, 8:06 AM ET

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

56/100

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

Deep Value

Momentum

Weakening

Sentiment

Very Bullish

Risk resilience

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

OptimizeRx Corp. is digital health company, engaged in the provision of digital health messaging via electronic health records, which serve as a direct channel for pharmaceutical companies to communicate with healthcare providers. It offers electronic health record (EHR) workflow solutions which include financial messaging, patient education, and brand messaging and brand support. The company was founded by David A. Harrell in 2006 and is headquartered in Waltham, MA.

Industry: Medical - Healthcare Information Services
Sector: Healthcare
Headquarters: US
CEO: Stephen L. Silvestro
Listed since: Nov 28, 2007
Employees: 133

Market position

Day range

Current $7.71

$7.59$8.07

52-week range

Current $7.71

$4.54$22.25

Open: $8.07
Previous close: $7.96
Volume: 131.49K; 0.33× average
Average volume: 397.99K; Average daily volume
Market cap: 144.68M USD
Beta: 1.05; Market reference 1
50-day average: $6.3894; +20.67% above average
200-day average: $8.7782; -12.17% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value: 230.23M USD
P/E (TTM): 31.65×
P/B (TTM): 1.1×
P/S (TTM): 1.47×
EV / EBITDA: 13.89×
Earnings yield: 2.26%
Free cash flow yield: 8.20%
Dividend yield: 0.00%

Profitability & efficiency

Gross margin: 72.14%
Operating margin: 11.45%
Net margin: 4.66%
Return on equity: 4.00%
Return on assets: 2.90%
Return on invested capital: 5.56%

Financial health

Debt / equity: 0.15×
Current ratio: 3.04×
Altman Z-score: 3.08
Piotroski F-score: 7 of 9

Earnings

Latest fiscal-year EPS: 0.27; FY2025
Latest fiscal-year revenue: 109.43M USD; FY2025 · +18.78% year over year
Next fiscal-year EPS consensus: 0.912; FY2026 · 3 analysts
Next fiscal-year revenue consensus: 96.62M USD; FY2026 · 5 analysts

Annual EPS trend

Reported history and fiscal-year consensus

ReportedConsensus forecast

Annual revenue trend

Reported history and fiscal-year consensus

ReportedConsensus forecast

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$10.25

32.94% upside

Past 12 months12-month forecastHigh $12.00Average $10.25Low $7.00

Rating distribution

15 ratings

Strong buy00%

Buy1173%

Hold427%

Sell00%

Strong sell00%

Recent analyst actions

10 institutions

Roth CapitalmaintainBuyMar 6, 2026

OPRX news

defenseworld.netAug 13, 2026

Dimensional Fund Advisors LP Purchases 102,661 Shares of OptimizeRx Corp. $OPRX

Dimensional Fund Advisors LP grew its position in shares of OptimizeRx Corp. (NASDAQ: OPRX) by 22.3% during the undefined quarter, according to the company in its most recent filing with the Securities and Exchange…

Read source

marketbeat.comAug 12, 2026

OptimizeRx Q2 Earnings Call Highlights

OptimizeRx NASDAQ: OPRX reported second-quarter fiscal 2026 revenue of $20.5 million, down 30% from $29.2 million a year earlier, while adjusted EBITDA totaled $4.9 million, management said on its earnings call. The…

Read source

seekingalpha.comAug 12, 2026

OptimizeRx Corporation (OPRX) Q2 2026 Earnings Call Transcript

Read source

zacks.comAug 12, 2026

OptimizeRx Corp. (OPRX) Q2 Earnings and Revenues Top Estimates

OptimizeRx Corp. (OPRX) came out with quarterly earnings of $0.16 per share, beating the Zacks Consensus Estimate of $0.11 per share. This compares to earnings of $0.24 per share a year ago.

Read source

globenewswire.comAug 12, 2026

OptimizeRx Announces Finance Leadership Appointments to Support the Next Phase of Growth

The Company Names Andy D'Silva as the next Chief Financial Officer and Heather Favazza as Chief Accounting Officer effective January 1, 2027

Read source

globenewswire.comAug 12, 2026

OptimizeRx Reports Second Quarter 2026 Financial Results and Updates Fiscal Year 2026 Guidance

– Q2 revenue totals $20.5 million– Q2 net loss and adjusted EBITDA of $(0.7) million and $4.9 million, respectively– Reaffirms fiscal year 2026 revenue guidance of $95 - $100 million and adjusted EBITDA guidance of $21 -…

Read source